Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab

By Scartozzi Mario   Giampieri Riccardo   Loretelli Cristian   Mandolesi Alessandra   Prete Michela del   Biagetti Simona   Alfonsi Simona   Faloppi Luca   Bianconi Maristella   Bittoni Alessandro   Bearzi Italo   Cascinu Stefano  

Future Oncology, Vol. 9, Iss. 8, 2013-08 ,pp. : 1207-1214

Future Medicine

Access to resources Recommend Favorite

Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer

By Larsen Finn Ole   Pfeiffer Per   Nielsen Dorte   Skougaard Kristin   Qvortrup Camilla   Vistisen Kirsten   Fromm Anne-Lene   Jøørgensen Trine L.   Bjerregaard Jon K.   Hoegdall Estrid   Jensen Benny V.  

Acta Oncologica, Vol. 50, Iss. 4, 2011-05 ,pp. : 574-577

Informa Healthcare

Access to resources Recommend Favorite

Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS

By Tural Deniz   Batur Sebnem   Erdamar Sibel   Akar Emre   Kepil Nuray   Mandel Nil   Serdengeçti Süheyla  

Tumor Biology, Vol. 35, Iss. 2, 2014-02 ,pp. : 1041-1049

Springer Publishing Company

Access to resources Recommend Favorite

Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS

By Kishiki Tomokazu   Ohnishi Hiroaki   Masaki Tadahiko   Ohtsuka Kouki   Ohkura Yasuo   Furuse Jyunji   Watanabe Takashi   Sugiyama Masanori  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 749-757

Springer Publishing Company

Access to resources Recommend Favorite

Cetuximab in the first-line therapy of metastatic colorectal carcinoma: not so CRYSTAL clear

By Windsor Alastair CJ   Cohen Richard   Jiao Long R   Stebbing Justin  

Future Oncology, Vol. 4, Iss. 6, 2008-12 ,pp. : 741-744

Future Medicine

Access to resources Recommend Favorite